COMPANY PROFILE

Kivu Bioscience

Explore full profile

Advanced ADC technologies enhancing cancer treatment precision and safety with improved manufacturability

San Mateo, United StatesFounded 2024Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2024

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Kivu Bioscience

Kivu Bioscience is at the forefront of developing next-generation transformative assets in the biotechnology sector, specifically focusing on Antibody-Drug Conjugates (ADCs) for cancer treatment. The company employs proprietary ADC technologies that enhance the precision and effectiveness of cancer therapies. By targeting specific proteins like asparagine 297, Kivu Bioscience produces highly homogenous products, offering a distinct manufacturing advantage over traditional conjugation methods. This approach not only improves the stability and efficacy of the ADCs but also reduces off-target side effects, thereby enhancing patient safety profiles. Kivu Bioscience primarily serves the healthcare and pharmaceutical industries, working closely with clinical researchers and healthcare providers to bring innovative cancer treatments to market. The company operates within the biotechnology market, leveraging its expertise to efficiently progress its programs to clinical proof of concept. Kivu Bioscience generates revenue through partnerships, licensing agreements, and the commercialization of its proprietary technologies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2024
Headquarters: San Mateo, United States
Employees: 25
Open positions: None listed
Dealroom signal: 27.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Oct 2024	$92M	$368M	Gimv · Novo Holdings · BioGeneration Ventures · HealthCap	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Kivu Bioscience website traffic

Latest recorded traffic for Kivu Bioscience is 1.8K monthly website visits, down 5.3% over the last three months.

Latest monthly visits1.8K 3-month web change-5.3%

Monthly website visitsNov 2024–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Senior Medical Director/Medical Director Clinical DevelopmentSan Mateo, CA · Other · Aug 25, 2026 Executive Director/Vice President, Clinical Development, OncologySan Mateo, CA · Other · Aug 24, 2026 Senior Director/Executive Director, Biostatistics and Statistical ProgrammingSan Mateo, CA · Data Science & Engineering · Aug 23, 2026 Director/Senior Director, Clinical Development OperationsSan Mateo, CA · Other · Aug 23, 2026

4 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
FMFocal MedicalApplying our sophisticated technology platforms to revolutionize the way drugs are delivered to improve patient healthcare outcomes	Cary, United States	Acquired	4	$12M	—
TWTwisterbiotechGene therapies for cancers and autoimmune diseases	Houston, United States	Operational
CTCV6 TherapeuticsCombination therapies enhancing cornerstone cancer and inflammatory treatments	Belfast, United Kingdom	Operational
ABAelius BiotechContract research company specialising in modelling the aero-digestive tract without the use of animal testing	Newcastle upon Tyne, United Kingdom	Operational
LBLeucid BioNext-generation CAR-T cell therapies for refractory cancers	London, United Kingdom	Operational
VBViaNautis BioPolymer nanoparticle platform for targeted intracellular genetic delivery	Cambridge, United Kingdom	Operational
NTNucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine	Oxford, United Kingdom	Operational
RBRosa BiotechAI-driven biosensing and diagnostics company providing outcome-focused biosensing for early disease diagnosis and for use in industrial biotechnology	Bristol, United Kingdom	Operational